Home
|
Learning Center
|
中文版
Publications
站内成果搜索:
搜索
阿伐他汀钙联合低分子肝素治疗78例肾病综合征的疗效观察
阿法替尼
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo
Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme
Afatinib in the treatment of breast cancer
Afatinib for the treatment of advanced non-small-cell lung cancer
Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis
阿伐他汀对高胆固醇血症ApoE基因敲除小鼠肝脏骨桥蛋白表达的影响
Afatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model
阿伐托他汀钙对急性冠脉综合征患者C-反应蛋白和IL-6的影响
阿法替尼和吉非替尼分别联合培美曲塞对人肺腺癌细胞作用的研究
阿法替尼的合成路线图解
阿法替尼与PF-04691502单用及联合对H1975细胞体外抗肿瘤作用研究
Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1
Afatinib Reduces STAT6 Signaling of Host ARPE-19 Cells Infected with Toxoplasma gondii
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naive EGFR L858R-Induced Lung Adenocarcinoma
Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report
Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A
Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial
Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo
Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation
阿伐他汀钙治疗冠心病的临床疗效及其对细胞因子TNF-α、CRP和IL-10的影响
Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: A case report
阿伐他汀对ApoE基因敲除小鼠海马和大脑皮质HDAC4和pCREB表达的影响
Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
Afatinib is Especially Effective Against Non-small Cell Lung Cancer Carrying an EGFR Exon 19 Deletion
Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial(aEuro)
Afatinib down-regulates MCL-1 expression through the PERK-eIF2 alpha-ATF4 axis and leads to apoptosis in head and neck squamous cell carcinoma
Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence
Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status
阿法替尼对人卵巢癌细胞的增殖抑制作用及其机制研究
阿伐他汀通过PI3K/Akt/mTOR途径调节白血病细胞自噬的作用及机制
阿伐他汀对高胆固醇血症ApoE基因敲除小鼠肝脏骨桥蛋白表达的影响及其分子机制
Afatinib and lung cancer
Afatinib, Erlotinib and Gefitinib in the First-Line Therapy of EGFR Mutation-Positive Lung Adenocarcinoma: A Review
Afatinib (BIBW 2992) development in non-small-cell lung cancer
Afatinib with Concurrent Radiotherapy in a Patient with Metastatic Non-Small Cell Lung Cancer
Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head %26 Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial
Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo
Afatinib (BIBW 2992)
Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials
Afatinib in NSCLC harbouring EGFR mutations
Afatinib-Related Nonhematologic Adverse Events: Is Common Evaluation Enough for Now?
Afatinib in the treatment of head and neck squamous cell carcinoma
Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers
Afatinib for lung cancer: let there be light?
Afatinib inhibits proliferation and invasion and promotes apoptosis of the T24 bladder cancer cell line
Afatinib: A Review of Its Use in the Treatment of Advanced Non-Small Cell Lung Cancer
Afatinib: First Global Approval
Afatinib for an elderly patient with chronic kidney disease
Afatinib ameliorates osteoclast differentiation and function through downregulation of RANK signaling pathways
Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition
Afatinib for the treatment of non-small cell lung cancer
Afatinib in squamous cell carcinoma of the head and neck
阿法替尼的合成工艺改进
阿伐他汀联合贝那普利治疗早期糖尿病肾病临床观察
阿法替尼合成工艺研究
阿法替尼治疗晚期非小细胞肺癌有效性和安全性的系统评价
阿法替尼对人乳腺癌细胞增殖与凋亡的影响及机制研究
阿法替尼在NSCLC中的应用与展望
Afatinib for the treatment of metastatic non-small cell lung cancer
Afatinib plus Cetuximab First-line in EGFR-Mutant Lung Cancer-Letter
Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress
Afatinib successfully treated leptomeningeal metastasis during erlotinib treatment in a patient with EGFR-mutant (Exon18:G719S) lung adenocarcinoma as a second-line chemotherapy
Afatinib in lung cancer harboring EGFR mutation in the LUX-Lung trials: six plus three is greater than seven?
Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors
Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors
Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data
Afatinib: A Review in Advanced Non-Small Cell Lung Cancer
Afatinib plus chemotherapy versus chemotherapy alone after progression on afatinib: new insights on old question?
Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for thetreatment of advanced non-small-cell lung cancer
Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC
Afatinib Decreases P-Glycoprotein Expression to Promote Adriamycin Toxicity of A549T Cells
Afatinib restrains K-RAS-driven lung tumorigenesis
Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea
Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab
Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC